Charged Alpha logo
CHARGED ALPHA
Stock Analysis
BAX Healthcare Latest YouTube: Q1 2026 Published 2026-05-02

Baxter International Inc.

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest earnings video

BAX Stock: Revenue Beats, EPS Misses — Q1 2026

Published 2026-05-02

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
Q1 2026
2026-05-02
Podcast available
Yes
Current price
$26.34
-0.31 (-1.16%)
Trailing / Forward P/E
Forward: 12.93x
Market cap / Volume
Volume:
Revenue / Earnings Growth
5.3%
Earnings: 36.8%
Margins
14.4% op
Gross: 34.1% · Net: -9.3%
Balance sheet
1.95x current
Debt / Equity: 156.4
52-week range / Beta
$15.73 - $30.00
Beta: 0.59
Analyst target
$28.73
Upside: 9.1%
Cash / shareholder return
7.35% FCF yield
Dividend yield: 0.76%

Company context

Industry: Medical Instruments & Supplies
Country: United States
Employees:
Price to book: 2.19x
Return on equity: -14.4%
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Price chart

Market context for BAX

Competitive view

BAX vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

Baxter International Inc. latest YouTube video thumbnail YouTube
Baxter International Inc.
BAX
Latest video
Q1 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.
Intuitive Surgical latest YouTube video thumbnail YouTube
Intuitive Surgical
ISRG
Latest video
Q2 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Johnson & Johnson latest YouTube video thumbnail YouTube
Johnson & Johnson
JNJ
Latest video
Q2 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
BAX
$13.62B
Baxter International Inc.
ISRG
$135.72B
Intuitive Surgical
JNJ
$651.25B
Johnson & Johnson
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
BAX
Baxter International Inc.
ISRG
43.5x
Intuitive Surgical
JNJ
31.4x
Johnson & Johnson
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
BAX
12.9x
Baxter International Inc.
ISRG
31.4x
Intuitive Surgical
JNJ
22.0x
Johnson & Johnson
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
BAX
5.3%
Baxter International Inc.
ISRG
18.5%
Intuitive Surgical
JNJ
6.6%
Johnson & Johnson
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
BAX
36.8%
Baxter International Inc.
ISRG
26.5%
Intuitive Surgical
JNJ
-0.9%
Johnson & Johnson
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
BAX
14.4%
Baxter International Inc.
ISRG
33.6%
Intuitive Surgical
JNJ
29.2%
Johnson & Johnson
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
BAX
34.1%
Baxter International Inc.
ISRG
66.7%
Intuitive Surgical
JNJ
68.1%
Johnson & Johnson
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
BAX
-9.3%
Baxter International Inc.
ISRG
28.4%
Intuitive Surgical
JNJ
21.5%
Johnson & Johnson
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
BAX
-14.4%
Baxter International Inc.
ISRG
17.4%
Intuitive Surgical
JNJ
25.7%
Johnson & Johnson
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
BAX
7.3%
Baxter International Inc.
ISRG
1.9%
Intuitive Surgical
JNJ
2.6%
Johnson & Johnson
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
BAX
156.45x
Baxter International Inc.
ISRG
Intuitive Surgical
JNJ
57.71x
Johnson & Johnson
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
BAX
1.95x
Baxter International Inc.
ISRG
4.96x
Intuitive Surgical
JNJ
1.09x
Johnson & Johnson
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
BAX
0.59
Baxter International Inc.
ISRG
1.46
Intuitive Surgical
JNJ
0.23
Johnson & Johnson
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
BAX
0.8%
Baxter International Inc.
ISRG
Intuitive Surgical
JNJ
2.0%
Johnson & Johnson
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
BAX
9.1%
Baxter International Inc.
ISRG
26.2%
Intuitive Surgical
JNJ
0.8%
Johnson & Johnson

Episode timeline

Episode archive for BAX

Each row is one earnings episode with every verified platform link available.

Q1 2026
Episode live
2026-05-02
Published youtube podcast complete
BAX Stock: Revenue Beats, EPS Misses — Q1 2026
Quarterly earnings-analysis entry for Baxter International Inc.. Use the links on the right to open the video or podcast episode.